Antiphospholipid antibodies and myocardial infarction
Antiphospholipid antibodies and myocardial infarction
复制标题
抗磷脂抗体与心肌梗塞
DOI：
10.1177/096120339800700229
复制
发表时间：
1998
期刊：
影响因子：
2.6
通讯作者：
O. Vaarala
中科院分区：
文献类型：
--
作者：
O. Vaarala
在前瞻性研究中，在心肌梗死（MI）患者中观察到心磷脂结合抗体和氧化低密度脂蛋白（LDL）自身抗体水平升高。这些结果表明，抗磷脂抗体可能有助于MI的发展。动脉粥样硬化性心脏病发病机制中的“氧化修饰假说”是基于LDL的氧化、其在动脉壁中的积聚以及动脉粥样硬化中慢性炎症的发展。最近有证据表明，SLE患者的脂质过氧化作用增强，并与抗磷脂抗体相关。还有流行病学数据显示SLE患者MI的风险显著增加。在这篇综述中，不同类型的抗磷脂抗体在动脉粥样硬化性心脏病的发展中的作用进行了评估，特别注意其潜在的致病机制和预防与抗磷脂抗体相关的MI的可能性。
In prospective studies, increased levels of cardiolipin-biding antibodies and autoantibodies to oxidized low-density lipoprotein (LDL) have been observed in patients with myocardial infarction (MI). These findings suggest that antiphospholipid antibodies may contribute to the development of MI. The ‘oxidative-modification hypothesis’ in the pathogenesis of atherosclerotic heart disease is based on the oxidation of LDL, its accumulation into arterial wall, and the development of chronic inflammation in the atheroma. Evidence of enhanced lipid peroxidation and its association with antiphospholipid antibodies has been recently reported in SLE patients. There is also epidemiological data showing a remarkably increased risk of MI in SLE. In this review, the role of different types of antiphospholipid antibodies in the development of atherosclerotic heart disease is evaluated with particular attention to their potential pathogenic mechanisms and the possibilities in the prevention of MI associated with antiphospholipid antibodies.
通过针对人纤溶酶原的 kringle 5-B 链段的单克隆抗体抑制纤溶酶原激活。
影响因子：
--
作者：
Church,WR;Messier,TL
通讯作者：
Messier,TL